There are six large production institutes of bio-logicals in China. The Kunming Institute of Medical Biology is the largest primate center, specializing in the production of live poliomyelitis vaccine and recently, of...There are six large production institutes of bio-logicals in China. The Kunming Institute of Medical Biology is the largest primate center, specializing in the production of live poliomyelitis vaccine and recently, of live hepatitis vaccine as well. All these institutes have research laboratories of their own which are engaged in the improvement of existing products and development of new ones. The National Institute for Control of Phamaceutical and Biological Products, created in 1951, is responsible for the direction of laboratories located in each production institute, for the testing of natively produced as well as imported biological products and for the preparation and issuing of national standards. Three additional bodies managed directly by the Ministry of Public Health are: Office for the Review of Drugs (including biologicals), Committee for Standardization of Biological Products and Office for Supervision of Drugs. These together consistiute the regulatory system in China.展开更多
This paper compares and analyzes the changes in the Chinese automobile market in recent years as well as the competition strategy of top makers of European, American, Japanese, Korean, and Chinese automobiles. In part...This paper compares and analyzes the changes in the Chinese automobile market in recent years as well as the competition strategy of top makers of European, American, Japanese, Korean, and Chinese automobiles. In particular, analysis is carried out on the cause of the rapid growth of European, American, and Korean makers in the passenger vehicle market and the slow growth of Japanese makers, especially, Toyota, Honda, and Chinese makers. In order to adapt to the environmental change in the Chinese automobile market, European and American makers like Volkwagen （VW） and General Motors （GM） have developed full model line-up strategies focusing on compact cars while utilizing the advantages of the annual production of their full model line-up and giving priority to local part procurement. What＇s more, Korea＇s Hyundai has converted its car model strategy from mid-sized cars into compact cars in accordance with the changes in the Chinese market. Through successful product development adjusting to local needs, Hyundai has firmly entrenched its brand name. For Honda and Toyota, the slow conversion from mid-sized cars to compact cars and the inability to decrease costs due to the slow development of local part procurement are the causes of their delayed development in the Chinese market.展开更多
文摘There are six large production institutes of bio-logicals in China. The Kunming Institute of Medical Biology is the largest primate center, specializing in the production of live poliomyelitis vaccine and recently, of live hepatitis vaccine as well. All these institutes have research laboratories of their own which are engaged in the improvement of existing products and development of new ones. The National Institute for Control of Phamaceutical and Biological Products, created in 1951, is responsible for the direction of laboratories located in each production institute, for the testing of natively produced as well as imported biological products and for the preparation and issuing of national standards. Three additional bodies managed directly by the Ministry of Public Health are: Office for the Review of Drugs (including biologicals), Committee for Standardization of Biological Products and Office for Supervision of Drugs. These together consistiute the regulatory system in China.
文摘This paper compares and analyzes the changes in the Chinese automobile market in recent years as well as the competition strategy of top makers of European, American, Japanese, Korean, and Chinese automobiles. In particular, analysis is carried out on the cause of the rapid growth of European, American, and Korean makers in the passenger vehicle market and the slow growth of Japanese makers, especially, Toyota, Honda, and Chinese makers. In order to adapt to the environmental change in the Chinese automobile market, European and American makers like Volkwagen （VW） and General Motors （GM） have developed full model line-up strategies focusing on compact cars while utilizing the advantages of the annual production of their full model line-up and giving priority to local part procurement. What＇s more, Korea＇s Hyundai has converted its car model strategy from mid-sized cars into compact cars in accordance with the changes in the Chinese market. Through successful product development adjusting to local needs, Hyundai has firmly entrenched its brand name. For Honda and Toyota, the slow conversion from mid-sized cars to compact cars and the inability to decrease costs due to the slow development of local part procurement are the causes of their delayed development in the Chinese market.
